- Orion projects its full-year net sales to be between €1.82 billion and €1.90 billion for 2025.
- The expected earnings before interest and taxes (EBIT) for Orion ranges from €590 million to €670 million.
- Orion is set to receive a milestone payment of €180 million related to Nubeqa sales, which will be recognized in the fourth quarter of 2025.
- As a result of this milestone payment, Orion has updated its full-year financial outlook for 2025, reflecting improvements in both net sales and operating profit expectations.
- The current market sentiment around Orion’s stock includes 7 buy ratings, 0 hold ratings, and 1 sell rating.
A look at Orion Oyj Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Orion Oyj, a company that specializes in developing pharmaceuticals and diagnostic kits, has received a mixed outlook based on Smartkarma Smart Scores. While the company scores moderately in the areas of value, growth, and momentum, its strengths lie in resilience and dividends, with higher scores in these categories. This indicates that Orion Oyj may be well-positioned to navigate challenges and provide stable returns to its investors alongside a consistent dividend income.
With a focus on hormone therapies, drugs for central nervous system and cardiovascular diseases, and urological disorders, as well as in vitro diagnostic kits, Orion Oyj appears to have a diverse portfolio aimed at addressing various medical needs. The company’s resilience score suggests it has the ability to withstand market fluctuations, while its dividend score indicates a commitment to rewarding shareholders. While growth and momentum scores are not as high, Orion Oyj‘s balanced performance across these factors paints a picture of a company that is striving for stability and sustainability in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
